The Inter-rater Reliability of the Turkish Version of Aphasia Rapid Test for Stroke

Sponsor
Ankara City Hospital Bilkent (Other)
Overall Status
Completed
CT.gov ID
NCT04386837
Collaborator
(none)
30
1
14.9
2

Study Details

Study Description

Brief Summary

The Aphasia Rapid Test (ART) is a bedside aphasia screening test developed originally in French. The purpose of this study is to assess the inter-rater reliability of the Turkish version of the ART in stroke patients.

Condition or Disease Intervention/Treatment Phase
  • Other: Turkish Aphasia Rapid Test

Detailed Description

The Aphasia Rapid Test (ART) was developed and validated originally in French to evaluate language skills in post-stroke patients (Azuar et al., 2013). It is a 26-point scale that takes less than 3 minutes to administer. The simplicity of the ART allows it be used bedside in acute post-stroke patients with little to no training needed. The items needed to administer the ART are also easy to access in healthcare settings (e.g., watch, pen, doctor's coat). Although the ART is not a diagnostic test, it is beneficial for tracking progress and determining prognosis in stroke patients.

The original ART was designed similar to the NIH Stroke Scale (NIHSS), a widely-used test in stroke patients. The NIHSS which assesses many areas of functioning (level of consciousness, gaze, visual ability, facial palsy, motor and sensory ability, limb ataxia, language, dysarthria, and extinction and inattention) was chosen because of its sensitivity to early changes in neurological status and high prognostic accuracy (http://www.nihstrokescale.org). The ART is an expanded version of the language section of the NIHSS. The total possible points on the ART is 26, which indicates the highest level of impairment. The test begins with the patient being asked to follow two one-step commands (up to two points each), a complex command (up to 3 points), repeat three nouns (up to 6 points), repeat a simple sentence (up to 2 points), and name three simple objects (up to 6 points). The next item requires a rating of dysarthria by the examiner (up to 3 points). On the final item, the patient is asked to name as many animals as they can think of in one minute (up to 4 points). With the exception of items 1a, 1b, and 6, there are no time restrictions on the test.

The purpose of the present study is to translate the original ART into Turkish to provide an efficient method for the evaluation of language skills in post-stroke Turkish-speaking patients and to assess its inter-rater reliability.

Study Design

Study Type:
Observational
Actual Enrollment :
30 participants
Observational Model:
Other
Time Perspective:
Prospective
Official Title:
The Inter-rater Reliability of the Turkish Version of Aphasia Rapid Test for Stroke
Actual Study Start Date :
Feb 1, 2020
Actual Primary Completion Date :
May 1, 2021
Actual Study Completion Date :
May 1, 2021

Arms and Interventions

Arm Intervention/Treatment
Aphasics

Patients with a left MCA infarct due to CVA will be included in the study. Each subject will be administered an aphasia screening test less than 3 minutes in length. The same test will be administered by another clinician to the same patient within a maximum of 12 hours to assess the inter-rater reliability of the test.

Other: Turkish Aphasia Rapid Test
Same

Outcome Measures

Primary Outcome Measures

  1. Inter-rater reliability [The test will be administered within a time frame of 12 hours by two clinicians]

    The inter-rater reliability between two clinicians administering the same test

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Inclusion Criteria:
  • Left MCA infarct due to CVA

  • Right hand dominant

  • Turkish as first language

  • CVA within the last 10 days

Exclusion Criteria:
  • Right or bilateral brain lesion

  • Previous stroke

  • Psychiatric disorder

  • Other neurological disorder

  • Cognitive impairment

  • Endotracheal entubation prohibiting responses to test

Contacts and Locations

Locations

Site City State Country Postal Code
1 Ankara City Hospital Ankara Turkey

Sponsors and Collaborators

  • Ankara City Hospital Bilkent

Investigators

  • Study Director: Mariam Kavakci, PhD, Ankara City Hospital Bilkent

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Mariam Kavakci, Speech-Language Pathologist Manager, Ankara City Hospital Bilkent
ClinicalTrials.gov Identifier:
NCT04386837
Other Study ID Numbers:
  • AnkaraCHBilkentFTR1
First Posted:
May 13, 2020
Last Update Posted:
Feb 22, 2022
Last Verified:
Feb 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Mariam Kavakci, Speech-Language Pathologist Manager, Ankara City Hospital Bilkent
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 22, 2022